Rezpegaldesleukin
- Generic Name
- Rezpegaldesleukin
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
- Conditions
- Alopecia Areata
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 94
- Registration Number
- NCT06340360
- Locations
- 🇵🇱
Nektar Investigative Site, Sosnowiec, ÅšlÄ…skie, Poland
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 396
- Registration Number
- NCT06136741
- Locations
- ðŸ‡ðŸ‡·
Nektar Investigative Site 5703, Zagreb, Grad Zagreb, Croatia
🇵🇱Nektar Investigator Site, Kraków, Poland
🇪🇸Nektar Investigative Site, Zaragoza, Spain
A Phase I Study of LY3471851 in Healthy Participants
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT05565729
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
A Single-Dose Study of LY3471851 in Healthy Participants
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT04998487
- Locations
- 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 81
- Registration Number
- NCT04677179
- Locations
- 🇺🇸
Care Access Research - Ogden, Ogden, Utah, United States
🇦🇺St. Vincent's Hospital, Fitzroy, Victoria, Australia
🇨🇦CISSS de la Montérégie - Centre Hôpital Charles-Le Moyne, Greenfield Park, Quebec, Canada
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 291
- Registration Number
- NCT04433585
- Locations
- 🇺🇸
Clinical Research Center of CT/NY, Danbury, Connecticut, United States
🇺🇸Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Northwell Health, Great Neck, New York, United States
A Study of NKTR-358 (LY3471851) in Healthy Participants
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT04380324
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
A Study of LY3471851 in Healthy Participants
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04133116
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
A Study of LY3471851 in Participants With Psoriasis
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04119557
- Locations
- 🇺🇸
Clinical Science Institute, Santa Monica, California, United States
🇺🇸Remington-Davis, Inc, Columbus, Ohio, United States
🇺🇸Paddington Testing Company Inc, Philadelphia, Pennsylvania, United States
A Study of LY3471851 in Participants With Eczema
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT04081350
- Locations
- 🇺🇸
Complete Dermatology, Sugar Land, Texas, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
🇺🇸Remington-Davis, Inc, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.